

July 21, 2004

CURRICULUM VITAE

MICHAEL C. PERRY, MD, FACP

Professor Department of Internal Medicine

Nellie B. Smith Chair of Oncology

Director, Division of Hematology/Medical Oncology

University of Missouri/Ellis Fischel Center

115 Business Loop 70 West, DC116.71

Columbia, MO 65203

I. PERSONAL INFORMATION

Birthplace _____

Birth Date _____

Citizenship _____

Social Security Number _____

II. EDUCATION

Year	Institution	Degree
1963 – 1966	Wayne State University Detroit, Michigan	BA (Liberal Arts)
1966 - 1970	Wayne State University Medical School Detroit, Michigan	MD
1972 - 1975	University of Minnesota Minneapolis, Minnesota	MS in Medicine

III. EMPLOYMENT

<u>Years</u>	<u>Title</u>	<u>Employer</u>
1970 - 1971	Intern - Straight Medicine	Mayo Graduate School of Medicine, Rochester, Minnesota
1971 - 1972	Resident - Internal	Mayo Graduate School

	Medicine	of Medicine, Rochester, Minnesota
1972 - 1974	Fellow in Hematology	Mayo Graduate School of Medicine, Rochester, Minnesota
1974 - 1975	Fellow in Oncology	Mayo Graduate School of Medicine, Rochester, Minnesota
1974 - 1975	Instructor in Medicine	Mayo Medical School, Rochester, Minnesota
1975 - 1980	Assistant Professor of Hematology and Medical Oncology	University of Missouri-Columbia Columbia, Missouri
1979 - 1980	Acting Director, Division of Hematology and Medical Oncology Oncology	University of Missouri-Columbia Columbia, Missouri
1980 - 1985	Associate Professor of Hematology and Medical Oncology	University of Missouri-Columbia Columbia, Missouri
October, 1981	Visiting Fellow in Neuro-Oncology	Memorial Sloan- Kettering Cancer Center
1982 - 1983	Director, Division Hematology and Medical Oncology	University of Missouri-Columbia Columbia, Missouri
1983 - 1991	Chairman, Department of Medicine	University of Missouri-Columbia Columbia, Missouri
1985 - Present	Professor of Medicine	University of Missouri-Columbia Columbia, Missouri

1991 - 1993	Medical Director	Ellis Fischel Cancer Center Columbia, Missouri
1991 - 1994	Senior Associate Dean	University of Missouri-Columbia Columbia, Missouri
1992 - 1994	Acting Director Division of Hematology and Medical Oncology	University of Missouri-Columbia Columbia, Missouri
1994 - present	Director, Division of Hematology and Medical Oncology	University of Missouri-Columbia Columbia, Missouri
2001-present	Medical Director-Outpatient Clinics	Ellis Fischel Cancer Center University of Missouri Hospitals and Clinics
2001-present	Associate Cancer Center Director for Clinical & Translational Research	University of Missouri Hospitals and Clinics
2003-present	Deputy Director	Ellis Fischel Cancer Center University of Missouri Hospitals and Clinics

IV. HONORS AND AWARDS

1970	Anna Albert Keller Research Award Wayne State University Medical School
1973 - 1975	American Cancer Society Clinical Fellow
1978	Fellow - American College of Physicians
1979 - 1981	American Cancer Society Junior Faculty Clinical Fellowship
1981	Missouri Society of Internal Medicine - "Young Internist of the Year"
1981	American Society of Internal Medicine - "Young Internist of the Year"
1985	University of Missouri Faculty Alumni Award
1994	Nellie B. Smith Chair of Oncology
1994	University of Missouri Medical School Honorary Alumni

1995	Leadership Award, Missouri Chapter, American College of Physicians
1996	Department of Internal Medicine Teaching Award
1996	Best Doctors in America-Central Region
1998-2003	Best Doctors in America
2000	Distinguished Southern Oncologist, Southern Association for Oncology
2001	Physician of the Year – Boone County Medical Society
2001-2003	America's Top Doctors
2002	Department of Internal Medicine Outstanding Teacher Award

V. MEMBERSHIP IN PROFESSIONAL SOCIETIES

1972 - Present	American Medical Association
1975 - Present	Boone County Medical Society
1975 - Present	Missouri State Medical Society
1975 - Present	American College of Physicians
1975 - Present	Cancer and Leukemia Group B
1976 - Present	Missouri Society of Internal Medicine
1976 - Present	American Society of Internal Medicine
1976 - Present	American Society of Hematology
1977 - Present	American Society of Clinical Oncology
1977 - 1987	Polycythemia Vera Study Group
1978 - Present	American Federation for Clinical Research
1983 - 1991	Association of Professors of Medicine
1985 - Present	Central Society for Clinical Research
1988 - Present	American Association for Cancer Research
1990 - Present	International Association for the Study of Lung Cancer
1990 - Present	Southern Medical Association
1990 - Present	Southern Association for Oncology

2003-Present American Society of Oncology Board of Directors

VI. COMMITTEES

A. National

- 1974 - 1976 Department of Health, Education, and Welfare House staff Effort Distribution Study
- 1979 - 1985 American Society of Internal Medicine Meetings Committee (Chairman 1984 - 1985)
- 1984 - 1986 American Society of Internal Medicine Annual Meeting Committee
- 1985 - 1990 American Society of Clinical Oncology Education and Training Committee
- 1985 - 1987 American Society of Clinical Oncology Public Relations Committee
- 1986 - 1988 AMA-Harvard Relative Value Study Technical Consultant
- 1986 - 1988 Association of Professors of Medicine Graduate Education Committee
- 1987 - 1989 American Society of Internal Medicine Academic Internists Committee
- 1988 - Pres American Medical Association Diagnostic and Therapeutic Technology Assessment (DATTA) Consultant Panel
- 1989 - 1991 American College of Physicians Medical Knowledge Self-Assessment Committee (MKSAP IX) (Oncology)
- 1990 - 2000 Editor of Proceedings, American Society of Clinical Oncology
- 1990 - 1995 American Society of Clinical Oncology Publications Committee
- 1994 - 1996 Southern Association for Oncology Meeting Committee
- 1997 - 2000 Southern Association for Oncology Board of Directors
- B. Cancer and Leukemia Group B Cancer Chemotherapy Group**
- 1982 - 1984 Executive Committee

- 1983 - Pres Board of Directors
- 1983 - 1984 Chairman Gastrointestinal Cancer Committee
- 1983 - 1986 Vice Chairman Publications Committee
- 1984 - 1995 Co-Chairman Respiratory Cancer Committee
- 1979 - 1981 Chairman Membership Committee

C. State/Local

- 1978 - Pres Missouri Society of Internal Medicine
President 1983 – 1984
- 1981 - 1991 Missouri State Cancer Control Advisory Commission – Chairman
- 1982 - 1991 American College of Physicians Governor’s Advisory Committee
- 1983 - 1984 Missouri State Medical Society Interspecialty Committee
- 1985 - 1988 Committee on Publications, Boone County Medical Society
- 1986 - 1990 Board of Directors, American Cancer Society Boone Unit, Missouri Unit
- 1996 - 1997 President, Boone County Medical Society
- 1995 - 2001 Chairman, State of Missouri Organ Donor Advisory Committee

D. Intramural

-
- 1982 - 1983 School of Medicine Resource Allocation and Development Committee
 - 1983 - 1986 School of Medicine Hospital Advisory Committee
 - 1984 - 1985 School of Medicine Dean’s Program Review Committee
 - 1984 - 1987 University Physicians Diagnosis Related Group Committee
-

1981 - 1991 University Physicians Clinic Management Committee

1983 - 1991 School of Medicine Council of Chairman

1983 - 1991 University Physicians Executive Committee

1983 - 1994 Medical Center Strategic Planning Committee

1991 - 1994 Risk Management Committee

1993 - Pres Electronic Health Care Committee

1997 - Pres Strategic Planning Group for Research

VII. EDITORIAL POSITIONS

1978 - 1990 Editorial Board, Missouri Medicine

1983 - Pres Editorial Board, Seminars in Oncology

1991 -2000 Editor, Program and Proceedings of the American Society of Clinical Oncology

1997 - 2006 Editor, American Society of Clinical Oncology Education Book

1997 - 2000 Editorial Board, Journal of Clinical Oncology

1999-Pres Associate Editor, Clinical Lung Cancer

2001-Pres Editor, Contemporary Oncology

2001-Pres Editorial Board, Current Treatment Options in Oncology

Ad Hoc Editorial Consultant

American Family Physician
Annals of Internal Medicine

Archives of Internal Medicine
 Blood
 Cancer
 Cancer Research
 Cancer Treatment Reports
 Chest
 Clinical Lung Cancer
 European Journal of Cancer and Clinical Oncology
 Experimental Lung Disease
 Investigational New Drugs
 Journal of Clinical Oncology
 Journal of the National Cancer Institute
 Lung Cancer
 Mayo Clinic Proceedings
 Medical & Pediatric Oncology
 Neurosurgery
 New England Journal of Medicine
 Seminars in Oncology

VIII. LICENSURE

1971 Michigan ()
 1972 Minnesota () Inactive
 1975 Missouri ()

IX. BOARD CERTIFICATION

1973 Diplomate - American Board of Internal Medicine
 1974 Diplomate - American Board of Internal Medicine
 Subspecialty Examination in Hematology
 1975 Diplomate - American Board of Internal Medicine
 Subspecialty Examination in Oncology
 1987 Diplomate - American Board of Internal Medicine
 Advanced Achievement in Internal Medicine (Core Internal Medicine,
 Hematology, Medical Oncology)

X. OUTSIDE SUPPORT

Acct #	Sponsor	Begin Date	End Date	Amount
()	()	11/2/95	10/21/00	()
()	()	2/22/00	2/21/00	()
()	()	4/1/00	5/31/00	()
()	()	8/31/00	8/30/00	()
()	()	11/29/95	4/12/00	()



9/12/00	8/31/00
3/15/00	10/15/00
4/30/00	4/29/00
4/1/00	3/31/00
2/20/00	2/19/00
7/9/00	10/26/00
3/25/00	3/24/00
7/15/00	7/14/00
3/1/99	2/28/00
11/24/98	9/1/00
3/17/99	2/28/00



XI. PUBLICATIONS

Refereed Papers

1. Palutke M, Kihn R, Perry M, Riddle J, Rector F, Rosenberg JC: Role of leukocytes and lysosomal enzymes in antibody-mediated (hyperacute) rejection of renal heterografts. *Laboratory Investigation* 27 (3):287-295, 1972.
2. Perry MC, Bayrd ED: Recurrent Felty's syndrome. *Mayo Clin Proc*, 49:875-878, 1974.
3. Perry MC, Kyle RA: The clinical significance of Bence Jones proteinuria. *Mayo Clin Proc*, 50:234-238, 1976.
4. Hoagland HC, Perry MC: Blast cell crisis in acute or chronic leukemia. *JAMA* 235:2888-2889, 1976.
5. Hoagland HC, Perry MC: Thrombocythemia (Thrombocytosis). *JAMA* 235:2330-2331, 1976.
6. Perry MC, Hoagland HC: The hyperviscosity syndrome. *JAMA* 236:392-393, 1976.
7. Perry MC, Hoagland HC, Wagoner RD: Uric acid nephropathy. *JAMA* 236:961-962, 1976.
8. Perry MC, Harrison EG, Burgert DO, Gilchrist GC: Familial Erythrophagocytic Lymphohistocytosis. *Cancer* 38:209-218, 1976.
9. Perry MC, Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Phase II studies of Dianhydrogalactitol and VP-16-213 in colorectal cancer. *Cancer Treat Rep* 60:1247-1250, 1976.
10. Kardinal CG, Perry MC: Colon cancer - 1977. *Missouri Med* 74:675-679, 1977.
11. Perry MC, Solinger A, Farhangi M, Luger A: Plasmacytomas and Mesothelioma. *Med Pediatr Oncol* 5:205-212, 1978.
12. Morris RW, Brubaker LH, Kardinal CG, Carolla RL, Perry MC: Adriamycin and cis-dichlorodiamine platinum in non-resectable and metastatic carcinoma of the lung. *Cancer Clinical Trials* 2:37-41, 1979.
13. White LA Jr, Perry MC, Kardinal CG, Kennedy BJ, Weiss RB, Carey RW: Phase II study of 5-fluorouracil, methyl CCNU, and daunomycin in colorectal cancer. A Cancer and Leukemia Group B study. *Cancer Treat Rep* 63:215-217, 1979.
14. Gruenewald RL, Perry MC, Henry PH: Leukemic iritis with hypopyon. *Cancer* 44:1511-1513, 1979.
15. Gruenewald RL, Perry MC: Thrombotic thrombocytopenic purpura. *Missouri Med*

- 76:316-319, 1979.
16. Clifton MD, Amromin D, Perry MC, Abadir R, Watts C: Spinal cord glioma following irradiation for Hodgkin's disease. *Cancer* 45:2051-2055, 1980.
 17. Perry MC, Hakami N: Rhabdomyosarcoma of the head and neck. *Ear, Nose, and Throat Journal* 59(4): 155-162, 1980.
 18. Perry MC, Holmes RA: The radioindium bone marrow image in acute (malignant) myelofibrosis. *J Nucl Med* 21:139-141, 1980.
 19. Templer J, Perry MC, Davis W: Carcinoma of unknown primary. *Arch Otolaryngol* 107:45-47, 1981.
 20. Niebrugge D, Monzon D, Perry MC, Hakami H: Osteogenic sarcoma following Hodgkin's disease. *Cancer* 48:416-441, 1981.
 21. Khojasteh A, Perry MC: Co-existence of diffuse lymphocytic lymphoma and polycythemia vera. *South Med J* 74:771-772, 1981.
 22. Vosika GJ, Briscoe K, Carey RW, O'Donnell JF, Perry MC, Budman D, Richards F III, Coleman M: Phase II study of diglycoaldehyde in malignant melanomas and soft tissue sarcomas. *Cancer Treat Rep* 65:823-825, 1981.
 23. Greco AG, Perry MC: Wilm's tumor in the adult. *South Med J*, 74:622-624, 1981.
 24. Khojasteh A, Taylor HM, Perry MC: Chronic myelocytic leukemia developing as a second cancer in a patient with chronic lymphocytic leukemia. *Ca - A Cancer Journal for Clinicians* 31:272-276, 1981.
 25. Donovan PB, Landaw SA, Dresch C, Gartenhaus WS, Goldbert JD, Ellis JT, Loeb V Jr, Perry MC, Pettitt RM, Pisciotta RT, Silver CT, Weinfeld A, Berk PD: Resistance to therapy of acute leukemia developing in the course of polycythemia vera. *Nouv Rev Fr Hematol* 23:187-192, 1981.
 26. Patchell R, Perry MC: Eosinophilic meningitis in Hodgkin's disease. *Neurology* 31:887-888, 1981.
 27. Khojasteh A, Holmes RA, Perry MC: Localization of bone lesions in multiple myeloma and plasmacytoma by scintigraphic and roetenographic techniques. *Iranian Journal of Medical Sciences* 12:51-61, 1981.
 28. Vosika G, Cooper MD, Vogelzang N, Comis R, Glidewell O, Morrison A, Perry MC, Berenberger J, Cuttner J, Schilling A, Coleman M, O'Donnell JF: Severe toxicity and death associated with zinostatin administration. *Cancer Treat Rep* 66:410-411, 1982.
 29. Khojasteh A, Perry, MC: Thyrotoxic erythrocytosis. *South Med J* 75:379-380, 1982.
 30. Perry MC: Chemotherapy, toxicity, and the clinician. *Semin Oncol* 9:1-4, 1982.
 31. Perry MC: Hepatotoxicity of chemotherapeutic drugs. *Semin Oncol* 9:65-74, 1982.
 32. Budman D, Ginsberg S, Perry MC, Weinberg V, Schein P, Hanson J, Coleman M, Wood W: Phase II trial of spirogermanium in breast adenocarcinoma. A Cancer and Leukemia Group B study. *Cancer Treat Rep* 66:1667-1668, 1982.
 33. Budman D, Forastiere A, Perloff M, Perry MC, Aisner J, Weinberg V: Aziridinylbenzoquinone (AZQ) in advanced breast cancer. A Cancer and Leukemia Group B Phase II trial. *Cancer Treat Rep* 66:1875-1876, 1982.
 34. Muscato M, Perry MC, Yarbrow JW: Chemotherapy of cervical carcinoma. *Semin Oncol* 9:373-387, 1982.
 35. Michalski KA, Miles JM, Perry MC: Unusual pH¹ translocation in a preleukemia. *Cancer Genet Cytogene* 6:89-90, 1982.

36. Perry MC, Forastiere AA, Richards F, Weiss RB, Anbar D: Phase II trial of bisantrene in advanced colorectal cancer. A Cancer and Leukemia Group B study. *Cancer Treat Rep* 66:1997-1998, 1982.
37. Farrell C, Perry MC, Bourgeois CH, Abernathie DL, Hakami N: Osteosarcoma - A complication of chemotherapy for Hodgkin's disease in children. *Am J Clin Oncol* 6:75-80, 1983.
38. Maule WF, Perry MC: Management of chemotherapy-induced nausea and emesis. *American Family Physician* 27(1):226-234, 1983.
39. Perry MC, Bauer JH, Farhangi M: Hypokalemia in acute myelogenous leukemia. *South Med J* 76:958-961, 1983.
40. Kardinal CG, Perry MC, Weinberg V, Wood W, Ginsberg S, Raju RN: Chemoendocrine therapy vs. chemotherapy alone for advanced breast cancer in post menopausal women: Preliminary report of a randomized study. A Cancer and Leukemia Group B study. *Breast Cancer Research and Treatment* 3:365-372, 1983.
41. Schilsky RL, Muscato JJ, Muscato MS, Perry MC: Phase I clinical evaluation of cytosine arabinoside and cisplatin in patients with advanced cancer. *Cancer Treat Rep* 68:1097-1102, 1984.
42. Amrein PC, Richards FR, Coleman M, Poulin RF, Holland JF, Weinberg V, Perry MC: Phase II study of amsacrine in patients with hepatoma. A Cancer and Leukemia Group B study. *Cancer Treat Rep* 68:923-924, 1984.
43. Perry MC: Mortality and morbidity in hemophilia. *Missouri Med* 81:133-135, 1984.
44. Forastiere A, Perry MC, Hughes AK, Wood WC: Bisantrene (NSC 337766)(CL 216,942) in advanced breast cancer. *Cancer Chemother Pharmacol* 13:226-229, 1984.
45. Yarbro CH, Perry MC: The effect of cancer therapy on gonadal function. *Semin Oncol Nurs* 1:3-8, 1985.
46. Maurer LH, Pajak T, Eaton W, Comis R, Chahinian P, Faulkner C, Silberfarb PM, Henderson E, Rege VB, Baldwin PE, Weiss R, Rafla S, Prager D, Carey R, Perry MC, Choi NC: Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung. A Cancer and Leukemia Group B Phase III study. *J Clin Oncol* 3:969-976, 1985.
47. Patterson WP, Winkelmann M, Perry MC: Zinc-induced copper deficiency: Megamineral sideroblastic anemia. *Ann Int Med* 103:385-386, 1985.
48. Perry MC, Kardinal CG, Weinberg V, Ginsberg SJ, Hughes A, Wood W: Chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil compared to chemotherapy plus hormonal therapy with tamoxifen in the treatment of advanced breast cancer: An interim analysis. *J Steroid Biochem* 23:1135-1140, 1985.
49. North WG, Ware J, Chahinian AP, Perry MC, O'Donnell J, Maurer LH: Clinical evaluation of the neurophysins as tumor markers in small cell lung cancer. *Recent Results in Cancer Research* 99:187-193, 1985.
50. Oster MW, Gray R, Panasci L, Perry MC: Chemotherapy for advanced pancreatic cancer: A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). *Cancer* 57:29-33, 1986.
51. Holland JC, Korzun AH, Tross S, Silberfarb P, Perry MC, Comis R, Oster MW: Comparative psychological disturbance in patients with pancreatic and gastric cancer.

- Am J Psychiatry 8:982-986, 1986.
52. Perry MC, Green MR, Mick R, Schein P: Cisplatin in patients with gastric cancer. A Cancer and Leukemia Group B Phase II study. *Cancer Treat Rep* 70:415-416, 1986.
 53. Ringenberg QS, Doll DC, Yarbrow JW, Perry MC: Tumors of unknown origin in bone marrow. *Arch Intern Med* 146:2027-2028, 1986.
 54. Aisner J, Weinberg V, Perloff M, Weiss R, Perry MC, Korzun A, Holland JF: Chemotherapy vs. chemoimmunotherapy (CAF vs CAFVP vs CMF each \pm MER) for metastatic carcinoma of the breast. A Cancer and Leukemia Group B Study. *J Clin Oncol* 5:1523-1533, 1987.
 55. Perry MC, Eaton WL, Propert KJ, et al: Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung: Cancer and Leukemia Group B Study 8083. *N Engl J Med* 316:912-918, 1987.
 56. Perry MC, Kardinal CG, Korzun AH, et al: Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B Protocol 8081. *J Clin Oncol* 5:1534-1545, 1987.
 57. Luikart SD, Propert KJ, Modeas CR, Green MR, Perry MC: High-dose etoposide therapy for extensive small cell lung cancer: A Cancer and Leukemia Group B Study. *Cancer Treat Rep* 71:533-534, 1987.
 58. Dorfman HD, Siegel HL, Perry MC, Oxenhandler R: Non-hodgkin's lymphoma of the synovium simulating rheumatoid arthritis. *Arthritis and Rheum* 30:155-161, 1987.
 59. Cella DF, Orofiamma B, Holland JC, Silberfarb PM, Tross S, Feldstein M, Perry MC, Maurer LH, Comis R, Orav EJ: The relationship of psychological distress, extent of disease, and performance status in patients with lung cancer. *Cancer* 60:1661-1667, 1987.
 60. Walker NJ, Perry MC: The changing face of leukocytosis. *Missouri Med* 84:697-698, November 1987.
 61. Kardinal CG, Perry MC, Korzun AH, et al: Responses to chemotherapy or chemohormonal therapy in patients with advanced breast cancer previously treated with adjuvant chemotherapy: A subset analysis of CALGB Study 8081. *Cancer* 61:415-419, 1988.
 62. Ringenberg QS, Perry MC, Propert KJ, Modeas C, Hirsh V, Weiss R, Richards F, Graziano S, Green M: Phase II trial of 4'-deoxydoxorubicin (DxDx) in non-small cell lung cancer: A Cancer and Leukemia Group B trial. *Med Pediatr Oncol* 16:27-29, 1988.
 63. Perry, MC: Gastrointestinal cancer and Seminars in Oncology. *Semin Oncol* 15:103-105, 1988.
 64. Perry, MC: A selective update on gastrointestinal cancer. *Semin Oncol* 15:189-192, 1988.
 65. Ringenberg QS, Doll DC, Patterson WP, Perry MC, Yarbrow JW: Hematologic effects of heavy metal poisoning. *South Med J* 81:1132-1139, 1988.
 66. Buescher LS, Perry MC: Precipitation of tethered cord syndrome by colonoscopy. *J Clin Gastroenterol* 10:468-9, 1988.
 67. North WG, Ware J, Maurer LH, Chahinian AP, Perry M: Neurophysins as tumor markers for small cell carcinoma of the lung. A Cancer and Leukemia Group B Evaluation. *Cancer* 62:1343-1347, 1988.

68. Tritz, DB, Doll DC, Ringenberg QS, Anderson S, Madsen R, Perry MC, Yarbrow JW: Bone marrow involvement in small cell lung cancer: Clinical significance and correlation with routine laboratory variables. *Cancer* 63:763-766, 1989.
69. Davis JR, Kern TG, Perry MC, Brownson RC, Harmon RG: Survey of cancer control attitudes among Missouri state legislators. *Missouri Med* 86:95-98, 1989.
70. Thomas AT, Perry MC: Autologous blood transfusion. *Missouri Med* 86:157-161, 1989.
71. Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, Eaton W, Zimmer B, Green M: Prognostic factors in small-cell carcinoma of the lung: An analysis of 1,521 patients. *J Clin Oncol* 7:344-354, 1989.
72. Sodhi N, Camilleri M, Camoriano JK, Low PA, Fealey RD, Perry MC: Autonomic function and motility in intestinal pseudo-obstruction caused by paraneoplastic syndrome. *Digestive Diseases and Sciences*. 34:1937-1942, 1989.
73. Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, Skarin A, Wopel S, Holland JF, Comis RL, Green MR: A randomized trial of anticoagulation with Warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. *J Clin Oncol* 7:993-1002, 1989.
74. Caldwell CW, Yesus YW, Loy TS, Bickel JT, and Perry MC: Acute leukemia/lymphoma of Plasmacytoid T-Cell Type. *Am Journal of Clin Path* 94:778-786, 1990.
75. Dillman RO, Seagren SL, Propert K, Guerra J, Eaton WL, Perry MC, Carey R, Frei EF III, and Greene MR: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. *N Engl J Med* 323:940-945, 1990.
76. Ringenberg S, Propert K, Muss HB, Weiss RB, Schilsky RL, Modeas C, Perry MC: Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin): Prospective studies with serial gated heart scans and reports of selected cases. *Invest New Drugs* 8:221-226, 1990.
77. Perry MC, Head C, Fairbanks VF, Jones RT, Taylor H, Proud V: Hemoglobin Columbia Missouri or $\alpha_2[88 (F9) \text{Ala} \rightarrow \text{Val}] \beta_2$: a new high oxygen affinity hemoglobin that causes erythrocytosis. *Mayo Clinic Proceedings* 66:5-10, 1991.
78. Loy TS, Diaz-Arias AA, and Perry MC: Familial erythrophagocytic lymphohistiocytosis. *Seminars in Oncology* 18:34-39, 1991.
79. Cella DF, Orav EJ, Kornblith AB, Holland JC, Silberfarb PM, Lee KW, Perry MC, et al: Socioeconomic status and cancer survival. *J Clin Onc* 9:1500-1509, 1991.
80. Oster MW, Schilsky RL, Faraggi D, Korzun AH, Perry MC, et al: Cytosine arabinoside and cisplatin for advanced breast cancer. *Cancer* 68:1696-1698, 1991.
81. Doll D, Goutsou M, Graziano S, Ellerton J, Bitran J, Modeas C, Herndon J, Perry M, and Green M: Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. *Cancer Chemother and Pharmacol* 29:71-74, 1991.
82. Komp, DM, Perry, MC: The histiocytic syndromes. *Semin in Onc* 18(1):1-2, 1991.
83. Aisner J, Goutsou M, Maurer L, Cooper R, Chahinian P, Carey R, Skarin A, Slawson R, Perry M, Green M: Intensive combination chemotherapy, concurrent chest irradiation and warfarin for the treatment of limited disease small cell lung cancer: A CALGB Pilot Study. *J Clin Onc* 10:8:1230-1236, 1992.

84. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al: A Meta-Analysis of thoracic radiotherapy for small-cell lung cancer. *N Eng J Med* 327:1618-1624, 1992.
85. Vokes EE, Lyss AP, Green MR, Herndon JE, Cooper B, Perry MC, Vinciguerra V, and Mason-Coughlin Kristine: Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: A randomized phase II study of the Cancer and Leukemia Group B. *Annals of Oncology* 3:727-732, 1992.
86. Lyss AP, Perry MC, Goutsou M, Propert K, Mason-Coughlin K, and Green MR: Intensive etoposide and carboplatin chemotherapy for advanced non-small cell lung cancer: A phase II trial of the Cancer & Leukemia Group B. *Am J Clin Onc* 15(5):399-404, 1992.
87. Green MR, Kreisman H, Doll DC, Lyss A, Clamon G, Goutsou M, Perry MC, and Propert KJ: Carboplatin in non-small cell lung cancer: An update on the Cancer and Leukemia Group B Experience. *Seminars in Oncology* 19(1), Suppl 2:44-49, 1992.
88. Aisner J, Whitacre MY, Budman DR, Propert K, Strauss G, Van Echo DA, and Perry MC: Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer. *Cancer Chemother & Pharmacol* 29(6): 435-8, 1992.
89. Brownson RC, Novotny TE, Perry MC: Cigarette smoking and adult leukemia, a meta-analysis. *Arch Intern Med* 153:469-475, 1993.
90. Luikart SD, Goutsou M, Mitchell, ED, Van Echo DA, Modeas CR, Propert KJ, O'Donnell J, Difino S, Perry MC, and Green MR: Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. *Am J Clin Oncol(CCT)* 16(2):127-131, 1993.
91. Patterson WP and Perry MC: Chemotherapeutic toxicities: A comprehensive overview. *Contemp Onc* 7:57-64, 1993.
92. Hinson JA and Perry MC: Small-cell lung cancer. *CA-A Cancer Journal for Clinicians* 43:216-225, 1993.
93. Clamon G, Herndon J, Perry MC, Ozer H, Kreisman H, Maher T, Ellerton J, and Green MR: Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer & Leukemia Group B. *J Natl Cancer Inst* 85(4):316-20, 1993.
94. Hansen H, Perry M, Arriagada R, Chastang C, Drings P, Österlind K, et al: Treatment evaluation. *Lung Cancer* 10(1):S7-S9, 1994.
95. Bunn P, Arriagada R, Choi N, Feld R, Gregor A, Perry M, et al: Combined modality therapy in small cell lung cancer. *Lung Cancer* 10(1):S25-S28, 1994.
96. Smith JP, Doll D, Croitoru R, Thornton C, Perry MC: Effects of octreotide on advanced colon cancer. *J Clin Gastroenterol* 18(3):245-247, 1994.
97. Arriagada R, Pignon JP, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, Onoshi T, Osterlind K, Tattersall MHN, and Wagner H: Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. *Anticancer Research* 14:333-336, 1994.
98. Ahles TA, Silberfarb PM, Rundle AC, Holland JC, Komblith AB, Canellos GP, Green MR, Perry MC: Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for Cancer and

- Leukemia Group B. *Psychother Psychosom* 62:193-199, 1994.
99. Kiang DT, Kennedy BJ, Younger J, Perry MC, Schilling A, Faraggi D, Korzun AH, Nowak B, and Wood W: Alternating chemotherapy for metastatic breast cancer - a pilot study based on tumor marker kinetics. *Cancer* 75(3):826-30, 1995.
 100. Bitran JD, Green MR, Perry MC, Hollis DR, Herndon JE for CALGB: A phase II study of recombinant interferon-gamma as maintenance therapy following combination chemotherapy for patients with extensive small cell lung cancer. A role for biologic maintenance therapy? *Am J Clin Oncol (CCT)* 18(1):67-70, 1995.
 101. Aisner J, Cirrincione C, Perloff M, Perry MC, Budman D, Abrams J, Panasci L, Muss H, Citron M, Holland J, Wood W, and Henderson IC: Combination chemotherapy for metastatic or recurrent carcinoma of the breast: a randomized phase III trial comparing: cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) versus vinblastine, doxorubicin, thiotepa, and halotestin (VATH) versus VATH alternating with cyclophosphamide, methotrexate, 5-fluorouracil, vinblastine, and prednisone (CMFVP) Cancer and Leukemia Group B Study 8281. *J Clin Oncol*, 13(6):1443-1452, 1995.
 102. Muscato JJ, Cirrincione C, Clamon G, Perry MC, Omura G, Berkowitz I, Reid T, Herndon JE, and Green MR: Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: A Cancer & Leukemia Group B Study. *Lung Cancer* 13:285-294, 1995.
 104. Murrell HJ, Perry MC, Muscato JJ, Dorr VJ, Wilkes JD, Doll DC: Hodgkin's disease: is staging laparotomy still necessary? *Semin Oncol* 22:15-25, 1995.
 105. Rapp JS, Perry MC: Extensive stage small cell lung cancer: determining suitability for outpatient management of febrile neutropenia. *Semin Oncol* 23:15-22, 1996.
 106. Mitchell EP, Perry MC, Luikart SD, Cirrincione CT, Van Echo DA, Herndon JE 2nd, Maurer LH, Clamon G, Green MR: A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a Cancer and Leukemia Group B study. *Lung Cancer* 15 (2):215-23, 1996.
 107. Perloff M, Norton L, Korzun A, Wood W, Carey R, Gottlieb A, Bank A, Silver R, Perry MC, Holland J: Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a noncross-resistant regimen: A CALGB Study. *J Clin Oncol* 14(5):1589-98, 1996.
 108. Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR: Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: A Cancer & Leukemia Group B Study (CALGB 8832), *Am J Clin Oncol* 1997 Feb;20(1):24-30.
 109. Perry, MC: Future Directions in the Therapy of Small Cell Lung Cancer. *Chest Surgery Clinics of North America* 7(1):183-193, 1997.
 110. Dawn B, Perry M: Bilateral non-Hodgkins lymphoma of the breast mimicking mastitis. *Southern Med Journal* 90(3):328-329, 1997.
 111. Dorr V, Perry, M: Adjuvant therapy for Stage I and II non-small cell lung cancer. *Hem/Onc Clinics of North America* 11(2): 267-278, April 1997.
 112. Perry MC, Deslauriers J, Albain KS, Choi NC, Depierre A, Johnston MR, Lacquet LK, Payne DG, Putnam JB, Sculier JP, Shepherd FA: Induction treatment for resectable non-small cell lung cancer. *Lung Cancer Supplement* 1, S15-S18, 1997.

113. Jett J, Reins R, Kvale P, McCloud T, Miller Y, Perry M, Sause W, Silvestri G, Stover D, Spiro S, Travis W: Pretreatment evaluation of non-small cell lung cancer. *Am J Respir Crit Care Med* 156: 320-332, 1997.
114. Niell, HB, Miller AA, Clamon GH, Perry MC, Crawford J, Green MR: A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. *Semin Oncol* 24, Suppl 12 130-134, 1997.
115. Perry MC: Future directions in the therapy of small cell lung cancer, *Chest Surg Clin N Am* Feb;7(1):183-94, 1997.
116. Maurer LH; Herndon JE 2nd; Hollis DR; Aisner J; Carey RW; Skarin AT; Perry MC; Eaton WL; Zacharski LL; Hammond S; Green MR: Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study, *J Clin Oncol* 15: 3378-87, 1997.
117. Ahles TA; Silberfarb PM; Herndon J 2nd; Maurer LH; Kornblith AB; Aisner J; Perry MC; Eaton WL; Zacharski LL; Green MR; Holland JC: Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B, *J Clin Oncol* 16: 1954-60, 1998.
118. Perry MC; Herndon JE 2nd; Eaton WL; Green MR: Thoracic radiation therapy added to chemotherapy for small-cell lung cancer; an update of Cancer and Leukemia Group B Study 8083. *J Clin Oncol* 16:2466-7, 1998.
119. Mehdi SA; Perry MC; Herndon JE 2nd; Crawford J; Young R; Graziano SL: A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. *J Interferon Cytokine Research* 18:623-627, 1998.
120. Vadlamani P; Dawn B; Perry MC: Catheter fracture and embolization from totally implanted venous access ports-three case reports, *Angiology* 49:1013-6, 1998.
121. Perry MC; Ihde DC; Herndon JE 2nd; Grossbard ML; Grethein SJ; Atkins JN; Vokes EE; Green MR: Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532, *Lung Cancer* 28:63-8, 2000.
122. Kornblith A, Herndon JE, Zuckerman E, Viscoli C, Horwitz R, Cooper MR, Lyndsay H, Tkaczuk KH, Perry MC, Budman D, Norton L, Holland JC: Social support as a buffer to the psychological impact of stressful life events in women with breast cancer, *Cancer*, 91:p443-454, Jan 15, 2001.
123. Keller SM, Sudeshna A, Wagner H, Herskovic A, Ritsuko K, Brooks BJ, Perry MC, Livingston RB, Johnson DH: A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. *New England Journal of Medicine*, 343(17) 1217-1222, 2000.
124. Wooldridge JE; Anderson CM; Perry MC: Corticosteroids in advanced cancer, *Oncology* 15(2), 225-234, February 2001.
125. King PD, Perry MC: Hepatotoxicity of Chemotherapy, *The Oncologist*; 6:162-176 2001
126. Abid SH, Malhotra V; Perry MC: Radiation-induced and chemotherapy induced pulmonary injury, *Current Opinion in Oncology*, Vol 13, No 4, p242-248, 2001.
127. Keller SM; Vangel MG; Adak S; Wagner H; Schiller JH; Herskovic A; Komaki R;

- Brooks BJ; Perry MC; Marks RS; Livingston RB; Johnson DH for Eastern Cooperative Oncology Group. The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. *Lung Cancer* 37: 303-309, 2002.
128. Berry D, Broadwater G, Klein J, Antman KH, Aisner J, Bitran J, Costanza M, Freytes C, Gale R, Henderson C, Lazarus H, McCarthy P, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz M: High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of Cancer and Leukemia Group B trials with data from the Autologous blood and marrow transplant registry. *Journal of Clinical Oncology* 30:743-750, 2002.
 129. Blackstock A, Il J, Paskett ED, Perry MC, Graziano S, Muscato JJ, Kosty MP, Akerley WL, Holland JC, Fleishman S, Green MR. Outcomes among African-American non/African-American patients with advanced non-small cell lung cancer receiving chemotherapy: report from the cancer and leukemia group B. *Journal of the National Cancer Institute* 94:284-90, 2002.
 130. Sachs B, Haider S, Balaraman R, Shahab N, Perry MC. Hepatotoxicity of chemotherapy. *Expert Opin Drug Safety*, 1 (4): 339-353, 2002.
 131. Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small cell lung cancer: Cancer and Leukemia Group B study 9431. *Journal of Clinical Oncology* 20 (20): 4191-4198, October 15, 2002.
 132. Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic A, Komaki R, Brooks BJ, Perry MC, Marks RS, Livingston RB, Johnson DH. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer (NSCLC). *Cancer*. Accepted.
 133. Govindan R, Read W, Faust J, Perry MC, McLeod H. Phase II study of Docetaxel and Irinotecan in Patients with Metastatic or Recurrent Esophageal Cancer: A Preliminary Report. Submitted.
 134. Belani, C, Ramalingam, S, Bartsis, Perry, MC. La Rocca, RV, Nattam, SR, Rinaldi, D, Clark, R, Mills, GM. Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial. Submitted.

Letters

1. Perry MC: Familiar colonic polyposis. *N Engl J Med* 295:507-508, 1976.
2. Perry MC: Cauteropyreophagia. *N Engl J Med* 296:821, 1977.
3. Perry MC: Silver Stools. *JAMA* 243:1809, 1980.
4. Buescher LS, Perry MC: Precipitation of the tethered cord syndrome by colonoscopy. *Journal of Clinical Gastroenterology*. 10(4):468-9, 1988.
5. Perry MC, McKinin EJ: The Paper Trail Versus the Invisible College. *Academic Medicine* 65:686-687, 1990.
6. King PD, Perry MC, Zanol K: Lymphoma in the setting of dermatitis herpetiformis: another case. *Dermatology* 190:253, 1995.

Reviews

1. Perry MC, Reviewer: The monoclonal gammopathies: Multiple myeloma and related plasma cell disorders. Robert A. Kyle and Edwin D. Bayrd. *Mayo Clin Proc* 52:404, 1977.
2. Perry MC, Reviewer: Medical complications of malignancy. Edited by Frank E. Smith and Montague Lane. *Ann Int Med* 101:890, 1984.
3. Perry MC: Subdural hemorrhage secondary to extramedullary hematopoiesis in Postpolycythemic myeloid metaplasia (comments). *Neurosurgery* 14:588-591, 1984.
4. Perry MC, Reviewer: Head and neck management of the cancer patient. Edited by Douglas E. Peterson, George Elias, and Stephen T. Sonis. *Ann Int Med* 107:438, 1987.
5. Perry MC, Reviewer: Cancer Medicine, Third Edition, Volumes 1 and 2. Edited by James F. Holland, Emil Frei, III, Robert C. Bast, Jr., Donald W. Kufe, Donald L. Morton, and Ralph R. Weichselbaum. *Journal of the National Cancer Institute* 86:555, 1994.
6. Perry MC, Reviewer: Cancer: Principles and practice of oncology, 4th edition. Edited by Vincent T. DeVita, Jr., Samuel Hellman, and Steven A. Rosenberg. *Journal of the National Cancer Institute* 86:555, 1994.
7. Perry MC, Reviewer: Textbook of Lung Cancer. Hansen H, editor, 2001.
8. Perry MC, Reviewer: Textbook of Lung Cancer, *Annals of Internal Medicine*, May 15, 2001.
9. Perry MC, Reviewer: Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, *New England Journal of Medicine*; 344:1723-24, May 2001.

Editor/Editorials

1. Perry MC (Guest Editor): Toxicity of Chemotherapy. *Semin Oncol* 9:1-154, 1982.
2. Perry MC (Guest Editor): Danni Da Chemioterapia Antineoplastica *Oncologia Clinica* 8:1-289, 1982.
3. Perry MC, (Guest Editor): Gastrointestinal Cancer. *Semin Oncol* 15:103-195, 1988.
4. Perry MC, (Editorial): Patients, Profits, and Progress. *Missouri Med* 86:375, 1989.
5. Perry, MC, (Editorial): Multimodality therapy for lung cancer. *Missouri Med* 86:733-734, 1989.
6. Brownson, RC, Perry, MC: (Editorial) Missouri leads the nation: And that needs to change. *Missouri Medicine* 88(2):71, 1991.
7. Perry MC, (Guest Editor): The Histiocytic Syndromes. *Semin Oncol* 18:1, 1991.
8. Perry MC: Toxicity: ten years later. *Semin Oncol* 19:5, 1992.

Invited Papers

1. Perry MC, Hakami H: Rhabdomyosarcoma of the head and neck. *Ear Nose Throat J* 59:27-38, 1980.
2. Maule WF, Perry MC: Management of chemotherapy-induced nausea and emesis. *Am Fam Physician* 27:226-234, 1983.
3. Brown H, Perry MC: The bleeding patient. *Topics in Emergency Medicine*, p. 28-33, July 1983.

4. King PD and Perry MC: Hepatotoxicity of Chemotherapeutic Agents and Oncologic Agents. Gastroenterology Clinics of North America. 24:969-990, 1995.

Book Chapters

1. Perry MC, Kardinal CG, Weinberg V, Ginsberg S, Wood W: Chemotherapy compared to chemotherapy plus hormonal therapy in the treatment of postmenopausal women with advanced breast cancer: An interim report in Current Controversies in Breast Cancer. GR Blumenschein, Editor. University of Texas Press, p 477-486, 1984.
2. Perry MC: Hepatotoxicity of chemotherapeutic agents in Toxicity of Chemotherapy. MC Perry and JW Yarbrow, Editors. Grune and Stratton. May 1984. p. 297-315.
3. Perry MC, Yarbrow JW: Complications of chemotherapy: An overview in Toxicity of Chemotherapy. MC Perry and JW Yarbrow, Editors. Grune and Stratton. May 1984. p. 1-19.
4. Perry MC, Yarbrow JW: Beneficial effects of chemotherapy toxicity in Toxicity of Chemotherapy. MC Perry and JW Yarbrow, Editors. Grune and Stratton. May 1984. p. 539-544.
5. Perry MC: Complications of chemotherapy in A Comprehensive Textbook of Oncology. Edited by SC Schimpff, AR Moosa, MC Robson. Williams and Wilkins, 1985. p. 244-256.
6. North WG, Ware J, Chahinian AP, Perry M, O'Donnell J, Maurer LH: Clinical evaluation of the neurophysins as tumor markers in small cell lung cancer in Recent Results in Cancer Research: Peptide Hormones in Lung Cancer. Edited by K Havemann, G Sorenson, C Gropp. Springer-Verlag, 1985. p. 187-193.
7. Perry MC: Cardiac metastasis in Cancer and the Heart. Edited by AS Kapoor. Springer-Verlag, 1986. p. 76-81.
8. Perry MC: Effects of chemotherapy on the heart in Cancer and the Heart. Edited by AS Kapoor. Springer-Verlag, 1986. p. 223-226.
9. Perry MC: Breast lump in Clinical Methods. Edited by HK Walker. WD Hall and JW Hurst. Butterworths, 1990 p. 804.
10. Perry MC: Pain management in Decision Making in Oncology. Edited by P Schein. BD Decker Inc., 1989 p. 222-225.
11. Perry MC: Complications of Chemotherapy in AR Moossa, SC Schimpff, MC Robson editors. A Comprehensive Textbook of Oncology, 2nd edition, Williams & Wilkins. Baltimore, 1991, p. 1706-1719.
12. Perry MC: Hepatotoxicity of Chemotherapeutic Agents in The Chemotherapy Source Book. Edited by MC Perry. Williams & Wilkins, 1992, p 635-647.
13. Perry MC: Combination Chemotherapy Programs in The Chemotherapy Source Book. Edited by MC Perry. Williams & Wilkins, 1992, p 756-779.
14. Perry MC: Chemotherapy of Gastrointestinal Cancer in The Chemotherapy Source Book. Edited by MC Perry. Williams & Wilkins, 1992, p 989-997.
15. Perry MC: Genitourinary, Gastrointestinal, and Other Complications in High Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Edited by JO Armitage, KH Antman. Williams & Wilkins, 1992.
16. Perry, MC: Lung Cancer in the Elderly. Principles of Geriatric Medicine and

- Gerontology. Third Edition. Edited by WR Hazzard, EL Bierman, JB Blass, WH Ettinger, and JB Halter. McGraw-Hill, 1993.
17. Donehower RC, Abeloff MD, Perry MC: Selection of patients for chemotherapy in Clinical Oncology. Editors Abeloff MD, Armitage JO, Lichter AS, and Niederhuber JE. Churchill Livingstone International, 1995.
 18. Perry MC: Genitourinary, Gastrointestinal, and Other Complications in High Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Second Edition. Edited by JO Armitage, KH Antman. Williams & Wilkins, 1995.
 19. Westgate SJ, Perry MC: Toxicity of combined modality therapy in Comprehensive Textbook of Thoracic Oncology. Williams and Wilkins, 1996.
 20. Shahab N, Perry MC: DNA topoisomerase inhibitors in The Chemotherapy Sourcebook Second Edition, Williams & Wilkins, 1996.
 21. King PD, Perry MC. Hepatotoxicity in The Chemotherapy Sourcebook Second Edition, Williams & Wilkins, 1996.
 22. Dorr VJ, Perry MC. Randomized Trials in Stages I and II Non-Small-Cell Lung Cancer, in Lung Biology in Health and Disease, Volume 140, Multimodality Treatment of Lung Cancer, Marcel Dekker, Inc., 2000.
 23. Perry, MC, Anderson, CM, Donehower, RC: Chemotherapy in Clinical Oncology. Second edition Editors Abeloff MD, Armitage JO, Lichter AS, and Niederhuber JE. Churchill Livingstone International, 2000.
 23. Perry MC, Longo DL. Late consequences of cancer and its treatment, in Harrison's 15th Edition of Principles of Internal Medicine, McGraw-Hill Medical Publishing Division, 2001.
 24. Bryer M; Perry MC. "Early Timing of Radiotherapy is Critical in Limited-Stage SCLC: Con", Controversies in Lung Cancer, A Multidisciplinary Approach, edited by Benjamin Movsas, Corey J. Langer and Melvyn Goldberg, Marcel, Dekker, Inc, New York, 2001.
 25. King PD, Perry MC. Hepatotoxicity in The Chemotherapy Sourcebook Third Edition, Williams & Wilkins, 2001
 25. Maghfoor I, Perry MC. Lung Cancer in the Elderly. Principles of Geriatric Medicine and Gerontology. Fourth Edition. Edited by WR Hazzard, EL Bierman, JB Blass, WH Ettinger, and JB Halter. McGraw-Hill, 1999
 26. Shahab N, Perry MC. Lung Cancer in the Elderly. Principles of Geriatric Medicine and Gerontology. Fifth Edition. Edited by WR Hazzard, EL Bierman, JB Blass, WH Ettinger, and JB Halter. McGraw-Hill, 2003.
 27. Perry M, King P. Hepatotoxicity of chemotherapy. UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA 2002.
 - 28.

Books

1. Perry MC and Yarbrow JW, editors. Toxicity of Chemotherapy. Grune and Stratton, 1984.
2. Braun SR, editor; Everett ED, Perry MC, Sunderrajan EV, associate editors. Concise Textbook of Pulmonary Medicine. Elsevier, 1989.
3. Perry MC, editor. The Chemotherapy Source Book, Williams & Wilkins, 1992.
4. Aisner J, Arriagada R, Green MR, Martini N, Perry MC, editors. Comprehensive

- Textbook of Thoracic Oncology. Williams & Wilkins, 1996.
5. Perry MC, editor. The Chemotherapy Source Book Second Edition, Williams & Wilkins, 1996.
 6. Perry MC, Anderson CM, Dorr VJ, Wilkes JD: Companion Handbook to The Chemotherapy Sourcebook, Lippincott, Williams & Wilkins, 1999.
 7. Perry MC, editor. The Chemotherapy Source Book Third Edition, Lippincott, Williams & Wilkins, 2001.

Abstracts (* = presented)

- *1. Perry MC, Kyle RA: Bence Jones proteinuria. Proceedings of Minnesota Society of Medicine, April 1975.
2. Sauer HI, Perry MC, Seay BJ: The geographic puzzle of pancreatic cancer. Proceedings of American Pancreatic Association Meeting, November 1977.
3. Perry MC, White L, Kardinal CG: 5-fluorouracil, methyl CCNU, and daunomycin in advanced colorectal adenocarcinoma. Proceedings of American Society of Clinical Oncology, April 1978.
- *4. Sorkin MI, Perry MC: Effects of cis-dichlorodiammine platinum (II) on glomerular filtration rate in renal plasma flow in a conscious rat. Proceedings of Midwest Section of the American Federation for Clinical Research, November 1978.
5. Sorkin MI, Perry MC: Effects of cis-dichlorodiammine platinum (II) on glomerular filtration rate in renal plasma flow in a conscious rat. Proceedings of American Society of Nephrology, November 1978.
6. Perry MC, Bauer J, Farhangi M: Hypokalemia in acute myelomonocytic leukemia. American Society of Hematology, November 1978.
7. Sorkin MI, Perry MC, Bopp NA: Effects of chronic salt loading on cisplatin nephrotoxicity in the rat. American Society of Nephrology, November 1979.
8. Perry MC, Davidson EM, Kardinal CG: Chemotherapy of recurrent squamous cell carcinoma of the head and neck. American Society of Clinical Oncology, May 1980.
9. Greco AO, Perry MC: Factors influencing accrual to protocol studies. American Society of Clinical Oncology, May 1980.
10. Perry MC, Eaton WL, Comis RL, Spaulding MB, Carey RW, Maurer LH: Simultaneous radiation therapy and chemotherapy in limited small cell cancer of the lung: A pilot study. American Society of Clinical Oncology, May 1981.
11. Aisner J, Weinberg V, Perloff M, Weiss R, Raich P, Perry MC, Wiernik P: Chemoimmunotherapy for advanced breast cancer: A randomized comparison of six combinations (CMF, CAF, vs. CAFVP) each with or without MER immunotherapy. A Cancer and Leukemia Group B study. American Society of Clinical Oncology, May 1981.
12. Perry MC, Farrell C, Hakami N, Nesbit M: Non-radiation induced osteogenic sarcoma in Hodgkin's disease. Hodgkin's Disease Symposium, September 1981.
13. Perry MC, Forastiere AA, Richards F II, Weiss RB, Anbar D: Phase II trial of anthracenedicarboxaldehyde in advanced colorectal cancer. A Cancer and Leukemia Group study. American Society of Clinical Oncology, May 1982.
- *14. Oster MW, Theologides A, Cooper MR, Rafla S, Hutchinson JL, Holland JH, Anbar D, Perry MC: Fluorouracil, adriamycin, and mitomycin (FAM) versus fluorouracil,

- streptozotocin, and mitomycin (FSM) in advanced pancreatic cancer. American Society of Clinical Oncology, May 1982.
- *15. Kardinal CG, Perry MC, Weinberg V, Wood W: A randomized study comparing chemotherapy alone to chemotherapy plus hormone therapy for the treatment of advanced breast cancer in post-menopausal women. Thirteenth International Cancer Congress, September 1982.
 - *16. Farrell C, Perry MC, Hakami N, Nesbit M: Non-radiation induced osteogenic sarcoma in Hodgkin's disease. Thirteenth International Cancer Congress, September 1982.
 - *17. Perry MC, Kardinal CG, Weinberg V, Wood W: Chemotherapy compared to chemotherapy plus hormonal therapy in the treatment of advanced breast cancer in post-menopausal women: A randomized study. Current Controversies in Breast Cancer, 26th Annual Clinical Conference, MD Anderson Hospital, November 1982.
 - *18. Perry MC, Kardinal CG, Weinberg V, Wood W: Chemotherapy compared to chemotherapy plus hormonal therapy in the treatment of advanced breast cancer in post-menopausal women: A randomized study. Current Controversies in Breast Cancer, Fifth Annual San Antonio Breast Cancer Symposium, November 1982.
 - 19. Forastiere AA, Budman DR, Perry MC: Phase II trials of aclacinomycin-A and bisantrene in advanced breast cancer. A Cancer and Leukemia Group B study. American Society of Clinical Oncology, May 1983.
 - *20. Holland JC, Silberfarb P, Feldman M, Bahna G, Perry MC, Comis R, Oster M, Piasetsky E: Comparative assessment of depression in patients with advanced pancreatic and gastric cancer. American Society of Clinical Oncology, May 1983.
 - *21. Schilsky RL, Brown M, Monaghan E, Muscato J, Perry MC: Phase I trial of cytosine arabinoside and cisplatin in patients with advanced cancer. American Society of Clinical Oncology, May 1983.
 - *22. Kardinal CG, Perry MC, Ginsberg S, Weinberg V, Hughes A, Wood WC: Chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) compared to chemotherapy plus hormonal therapy with tamoxifen (T) in the treatment of advanced breast cancer: A interim analysis. Proceedings International symposium on Chemotherapy in Combination with Hormonal Therapy in Breast Cancer, September 1983.
 - *23. Perry MC, et al: Chemotherapy with or without radiation therapy in limited small cell cancer of the lung. American Society of Clinical Oncology, May 1984.
 - *24. Chahinian AP, Ware J, Zimmer B, Comis R, Perry MC, et al: Evaluation of anticoagulation with warfarin and on alternating chemotherapy in extensive small cell cancer of the lung. American Society of Clinical Oncology, May 1984.
 - 25. Muchmore EA, Smeets HJ, Horton MC, Saleh F, Perry MC, Schilsky RL, Green MR: 5-fluorouracil (5FU) and cisplatinum (CDDP) chemotherapy for advanced colorectal cancer: A phase II trial. American Society of Clinical Oncology, May 1985.
 - *26. Chahinian AP, Ware JH, Zimmer B, Comis RL, Perry MC, Hirsh V, Skarin AT, Raich PC, Weiss RB, Green M, Carey RW: Update on anticoagulation with warfarin and on alternating chemotherapy in extensive small cell cancer of the lung. American Society of Clinical Oncology, May 1985.
 - *27. Kardinal CG, Perry MC, Korzun AH, Wood W: Response to chemotherapy or chemoendocrine therapy in patients with advanced breast cancer previously treated

- with adjuvant chemotherapy. Eighth Annual San Antonio Breast Cancer Symposium, November 1985.
- *28. Perry MC, Eaton WL, Chahinian P, Skarin A, Zimmer B, Propert KJ, Comis R, Green M: Chemotherapy (CT) with or without Radiation Therapy (RT) in Limited Small Cell Cancer of the Lung (SCCL). American Society of Clinical Oncology, May 1986.
 29. Ringenberg S, Perry MC, Propert K, Feldstein M, Zimmer B, Modeas C, Weiss RB, Richards F, Graziano S, Green M: Deoxydoxorubicin (DxDx) in extensive non-small cell lung cancer (NSCLC). American Society of Clinical Oncology, May 1986.
 - *30. Kardinal CG, Perry MC, Korzun AH, Wood W: Lack of differential response of estrogen receptor positive (ER+) vs. ER negative (ER-) breast cancer to cytoxan + adriamycin + 5-fluorouracil (CAF) chemotherapy. American Society of Clinical Oncology, May 1986.
 - *31. Cella DF, Orofiamma B, Holland JC, Silberfarb P, Tross S, Feldstein M, Maurer LH, Comis R, Perry MC, Green M: Relationship of psychological distress, extent of disease, and performance status in patients with lung cancer. American Society of Clinical Oncology, May 1986.
 - *32. Luikart SD, Propert K, Zimmer B, Green MR, Perry MC: High dose etoposide (VP-16) in ambulatory patients with extensive small cell cancer of the lung (SCCL). American Society of Clinical Oncology, May 1986.
 - *33. Perry MC, Eaton WL, Chahinian P, Skarin A, Zimmer B, Propert KJ, Comis R, Green M: Chemotherapy (CT) with or without Radiation Therapy (RT) in limited Small Cell Cancer of the Lung (SCCL). American Thoracic Society, May 1986.
 - *34. Aisner J, Propert K, Perry MC, Chahinian P, Richards F, Green M: Aggressive combination chemotherapy, chest and brain irradiation, and warfarin for the treatment of limited disease Small Cell Lung Cancer (SCLC). A Cancer and Leukemia Group B study. Proceedings Amer Soc Clin Oncol, March 1987.
 35. Ringenberg QS, Propert K, Perry MC, Weiss RB, Modeas C, Richards F, Graziano S, Hirsh V, Green M: Clinical cardiotoxicity of esorubicin: A prospective study with serial gated heart scans and report of selected cases. A Cancer and Leukemia Group B study. Proceedings Amer Soc Clin Oncol, March 1987.
 36. Kiang DT, Kennedy BJ, Korzun A, Younger J, Perry MC, Schilling A, Rice M, Wood W: Alternating chemotherapy for poor prognostic breast cancer. A Cancer and Leukemia Group B study. Proceedings Amer Soc Clin Oncol, March 1988.
 37. Schilsky RL, Perry MC, Citron ML: High dose 5-Fluorouracil (5-FU) therapy for advanced gastrointestinal (GI) malignancy. A Cancer and Leukemia Group B study. Proceedings Amer Soc Clin Oncol, March 1988.
 38. Luikart SD, Mitchell EP, Van Echo DA, Propert K, Modeas C, Perry MC, Green M: Phase I/II trial of etoposide (VP-16) and carboplatin (CBDCA) in untreated extensive small cell lung cancer. A Cancer and Leukemia Group B study. Proceedings Amer Soc Clin Oncol, 7:195, 1988.
 39. Lyss A, Perry M, Propert K, Green M: Etoposide (VP16)/carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC): A phase II study. A Cancer and Leukemia Group B study. Proceedings Amer Soc Clin Oncol, March 1988.
 40. Mitchell EP, Luikart SD, Van Echo DA, Propert K, Modeas C, Perry C, Green M: Etoposide (VP-16 and Cisplatin (DDP) in untreated extensive small cell lung cancer

- (SCLC): A dose-escalation study. A Cancer and Leukemia Group B study. *Proceedings Amer Soc Clin Oncol*, 7:206, 1988.
41. Mauer LH, Aisner J, Kwiatkowski D, Perry M, Propert K, Eaton W, Kreisman H, Green M: Adult respiratory distress syndrome (ARDS) in limited disease (LD) small cell lung cancer (SCLC). A Cancer & Leukemia Group B study. 3rd Workshop on SCLC, June 1989.
 42. Proud VK, Caldwell CW, Perry MC, Levine C, and Miles JH: A new syndrome of radioulnar synostosis, adult onset blood dyscrasia, and psoriasis provides evidence for a dominant gene that regulates cell maturation and differentiation. David Smith Dysmorphology Workshop, New York, April 26, 1989.
 43. Bitran J, Goutsou M, Clamon J, Perry M, Green M; A test of gamma interferon (g-INF) after initial chemotherapy for previously untreated extensive disease (PUED), small cell lung cancer (SCLC). *Proceedings Amer Soc Clin Oncol*, 1990.
 44. Luikart SD, MacDonald M, Herzan D, Modeas C, Goutsou M, Clamon G, Maurer H, Perry MC, Green M: Phase I trial of etoposide (VP-16), carboplatin (CBDCA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) for extensive small cell lung cancer (SCLC). *Proceedings Amer Soc Clin Oncol* March 1990.
 45. Luikart SD, Goutsou M, Mitchell ED, Van Echo DA, Modeas C, Propert K, Perry MC, Green MR: Phase II trial of high dose etoposide (VP-16) and carboplatin (CBDCA) in extensive small cell lung cancer (SCLC). *Proceedings Amer Soc Clin Oncol*, March 1990.
 - *46. Muscato J, Clamon G, Perry M, Omura G, Berkowitz I, Reid T, Green MR: Etoposide (VP-16) and cisplatin (DDP) at maximum tolerated dose (MTD) in non-small cell lung carcinoma (NSCLC). A Cancer and Leukemia Group B study. *Proceedings Amer Soc Clin Oncol*, March 1991.
 47. Lyss AP, Morrell LE, Perry MC. Triciribine phosphate (TCN-P) in advanced non-small cell lung cancer (NSCLC): Interim analysis of toxicity. *Proceedings Amer Soc Clin Oncol*, March 1991.
 - *48. Luikart SD, MacDonald M, Herzan D, Modeas C, Goutsou M, Clamon G, Maurer J, Perry MC, Green R. Ability of daily or twice daily granulocyte-macrophage colony stimulating factor (GM-CSF) to support dose escalation of etoposide (VP-16) and carboplatin (CBDCA) in extensive small cell lung cancer (SCLC). *Proceedings Amer Soc Clin Oncol*, March 1991.
 - *49. Clamon G, Goutsou M, Perry MC, Lyss A, Green MR. Interleukin-2 (IL-2) in extensive small cell lung cancer : A preliminary suggestion of activity. A Cancer and Leukemia Group B Study. *Proceedings Amer Soc Clin Oncol*, March 1991.
 50. Arriagada R, Ihde DC, Johnson DH, Pignon JP, Souhami RL, & the SCLC Meta-analysis Study Group: Meta-analysis of randomized trials evaluating the role of thoracic radiotherapy in limited small cell lung carcinoma (SCLC). *Lung Cancer, Journal of the International Association for the Study of Lung Cancer*, 6th World Conference on Lung Cancer, 10-14 November 1991, Melbourne, Australia.
 51. Arriagada R, Ihde DC, Johnson DH, Perry MC, Pignon JP, Souhami RL, and the SCLC Meta-analysis Study Group: Meta-analysis of randomized trials evaluating the role of thoracic radiotherapy in limited small cell lung carcinoma (SCLC). *Lung Cancer* 75:98, 1991.

52. Clamon G, Ozer H, Herndon J, Perry MC, Scalzo A, and Green MR: Activity of Interleukin-2 (IL-2) in patients (pts) with extensive small cell lung cancer. Proceedings of American Society of Clinical Oncology, May 1992.
53. Johnson DH, Arriagada R, Ihde DC, Perry MC, Pignon JP, RL Souhami for the SCLC Meta-analysis study group: Meta-analysis of randomized trials evaluating the role of thoracic radiotherapy (TRT) in limited-stage (LD) small cell lung cancer (SCLC). Proceedings of American Society of Clinical Oncology, May 1992.
54. Maurer LH, Herndon JE II, Hollis DR, Aisner J, Perry MC, Eaton WL Jr, Zacharski LL, Green MR: For the Cancer & Leukemia Group B: A randomized trial of Chemotherapy (CT) and Radiation Therapy (RT) with or without warfarin (W) for limited disease (LD) small cell lung cancer. Proceedings of American Society of Clinical Oncology, 1993.
55. Graziano S, Perry M, Herndon J, Crawford J: A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer (NSCLC). Proceedings of American Society of Clinical Oncology, 1995.
56. Morris D, Waller A, Tolbert V, Oliver C, Darr J, Frederick D, Johnson J, Perry MC: Complications of indwelling central venous access devices (VAD). Submitted to Proceedings of American Society of Clinical Oncology, 1995.
57. Shahab N, Wilkes J, Beyer S, Reynolds M, Demmy T, Westgate S, Ritchie D, Perry MC: Neoadjuvant chemoradiation followed by transhiatal esophagectomy for regional/locally advanced esophageal carcinoma. Proceedings of American Society of Clinical Oncology, 1996.
58. Perry MC, Herndon JE, Eaton WL, Green MR: Thoracic radiation therapy added to chemotherapy in limited small cell lung cancer: an update of Cancer & Leukemia Group B (CALGB) Study 8083: Proceedings of American Society of Clinical Oncology, 1996.
59. Morrell LE, Perry MC: Triciribine phosphate (TCN-P) in advanced non-small cell lung cancer (NSCLC): phase II trial. Proceedings of American Society of Clinical Oncology, 1996.
60. Rasool H, Maghfoor I, Farhangi M, Perry MC: Etoposide (VP-16) and Cisplatin as first line chemotherapy in stage III and IV non-small cell lung cancer. Proceedings of American Society of Clinical Oncology, 1996.
61. Shahab N, Doll DC, Perry MC, Roland W, Everett D: Hematological Manifestations of Ehrlichiosis. Proceedings of American Society of Hematology, December 1996.
62. Maghfoor I, Perry MC, Doll DC: Iron Stores in Chronic Myelomonocytic Leukemia. Proceedings of American Society of Hematology, December 1996.
63. Ihde DC, Perry MC, Herndon J, Atkins JN, Pillemer, EA, Shahinian AP, Green MR: Vinorelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer (NSCLC): CALGB 9532. Proceedings of American Society of Clinical Oncology, 1997.
64. Tucker R, Perry, MC, Young CL: A pilot study to evaluate famciclovir treatment of herpes labialis in immunocompromised cancer patients. Proceedings of American Society of Clinical Oncology, 1997.
65. Maghfoor I, Wilkes J, Kuvshinoff B, Westgate S, Bryer M, Perry MC, Miedema B, Doll D, Ota D: Neoadjuvant chemoradiotherapy with sphincter-sparing surgery for

- low lying rectal cancer. Proceedings of American Society of Clinical Oncology, 1997.
66. Perry M, Ihde D, Herndon J, Atkins N, Pillemer A, Chahinian A, Green A: Paclitaxel/ifosfamide chemotherapy for advanced non-small cell lung cancer (NSCLC): CALGB 9532. Proceedings of the American Society of Clinical Oncology, 1997.
- *67. Parnes HL, Berry D, Aisner J, Allen SL, Abrams JS, Cooper MR, Perry MC, Duggan DB, Sztatrowski TP, Cirrincione C, Henderson IC, Norton L: A randomized, phase III study of Cyclophosphamide ©, Doxorubicin (A) and 5-Fluorouracil (F) (CAF) with and without Leucovorin (L) for metastatic breast cancer: Cancer and Leukemia Group B Study (CALGB) 9140, Proceedings of the American Society of Clinical Oncology, 1998.
- *68. Perry MC, Ihde DC, Herndon J, Box J, Ijames L, Green JR: Paclitaxel/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Proceedings of the American Society of Clinical Oncology, 1998.
69. Niell HB, Miller AA, Clamon G, Perry MC, Crawford J, Green MR, Jones M: A phase I/II study evaluating the efficacy of carboplatin, etoposide and paclitaxel with G-CSF in extensive small cell lung cancer and stage IIIB and IV non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology, 1998.
70. Westgate SJ, Lilenbaum RC, Herndon II JE, Crawford J, Perry, MC, Green MR: Dose intensive non cross resistant alternating therapy for limited stage small cell lung cancer-a CALGB Phase II Trial. Proceedings of the American Society of Clinical Oncology, 1998.
- *71. Kornblith AB, Herndon JE, Zuckerman E, Viscoli C, Horwitz R, Weiss RB, Cooper MR, Crawford J, Borden E, Perry M, Budman D, Norton L, Holland JC: Can social support reduce breast cancer patients' psychological distress when faced with stressful life events?. Proceedings of the American Society of Clinical Oncology, 1999.
- *72. Berry DA, Broadwater G, Perry, MC, Aisner J, Costanza M, Parnes H, Henderson IC, Norton L, Antman K, Klein JP, Horowitz MM: Conventional-Vs high-dose therapy for metastatic breast cancer: comparison of cancer and Leukemia Group B (CALGB) and Blood and Marrow Transplant Registry (ABMTR) patients. Proceedings of the American society of Clinical Oncology, 1999.
- *73. Keller SM, Adak S, Wagner HJ, Herskovic A, Komaki R, Brooks BJ, Perry, MC, Livingston, RB, Johnson DH: Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: an intergroup trial (E3590). Proceedings of the American Society of Clinical Oncology, 1999.
74. Bandi S, Raheem M, Maghfoor I, Perry M: Eligibility of patients for cancer treatment protocols. Proceedings of the American Society of Clinical Oncology, 1999.
- *75. Raheem MA, Bandi SR, Perry MC: Study of mixed small cell and non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology, 1999.
- *76. Rasool HJ, Raheem MA, Perry MC: 1-Deamino-8-D-Arginine Vasopressin (DDAVP) produces hemostasis in patients with Glanzmann's Thrombasthenia: A Case Report, Blood 94/10, page 83B, November 1999.
- *77. Kornblith AB, Herndon JE, Zuckerman E, Viscoli C, Horwitz R, Weiss RB, Cooper MR, Crawford J, Broden E, Perry M, Budman D, Norton L, Holland JC: Can social

- support reduce breast cancer patients' psychological distress when faced with stressful life events? Proceedings of the American Society of Clinical Oncology, 1999.
- *78. Vokes EE, Leopold KA, Herndon JE II, Crawford J, Perry MC, Miller AA, Green MR: A randomized Phase II Study of Gemcitabine or Paclitaxel or Vinorelbine with Cisplatin as Induction Chemotherapy (Ind CT) and Concomitant Chemoradiotherapy (XRT) for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (CALGB Study 9431). Proceedings of the American Society of Clinical Oncology, 1999.
- *79. Wagner H, Adak S, Keller S, Herskovic A, Brooks BJ, Perry MC, Lickingston RB, Garland L, Wright D, Martin L, Johnson DH, Lee H: Patterns of failure for patients with resected N1 or N2 non-small cell lung cancer (NSCLC) following mediastinal irradiation with or without concurrent chemotherapy: an analysis of Eastern Cooperative Oncology Group (ECOG) E3590. Proceedings of the American Society of Clinical Oncology, 2000.
80. Theodoulou M, Llombart A, Cruciani G, Bloch R, Campos L, Tung N, Borges V, Perry MC, Rowland KM, Schuster M, Kneuper-Hall R, Hudis C: Pemetrexed Disodium (Alimta, LY231514, MTA) in locally advanced or metastatic breast cancer (MC) patients (Pts) with prior anthracycline or Anthracenedione and Taxane Treatment: Phase II Study. Proceedings of American Society of Clinical Oncology, 2000.
- *81. Belani CP, Barstis J, Clark R, Mills G, Perry MC, Nattam S: Phase II multicenter randomized trial of induction weekly paclitaxel (P) administered in combination with carboplatin © followed by weekly maintenance P vs. observation for patients (Pts.) with advanced & metastatic non-small cell lung cancer (NSCLC). 9th World Conference on Lung Cancer (IASLC), 2000.
- *82. Keller SM, Adak S, Wagner H, Herskovic A, Brooks BJ, Perry MC, Livingston RB, Johnson DH for the Eastern Cooperative Oncology Group Dept. of Surgery, The Beth Israel Medical Center, New York, NY, USA. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: an intergroup trial (E3590), 9th World Conference on Lung Cancer, IASLC, Tokyo, 2000.
- *83. Vokes EE, Leopold KA, Herndon JE, Crawford J, Perry MC, Miller AA, Green MR: CALGB Study 9431: A randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC), 9th World Conference on Lung Cancer, September 11-15, 2000, Tokyo, Japan, 2000.
- *84. C. Belani; J. Barstis; M. Perry; R. Larocca; S. Nattam; R. Clark; D. Rinaldi; G. Mills: Phase II Multicenter Randomized Trial of Weekly Paclitaxel (P) Administered in Combination with Carboplatin © Followed by Maintenance P Vs. Observation for Patients (Pts.) with Advanced & Metastatic Non-Small Cell Lung Cancer (NSCLC). No. 1287 Proceedings of American Society of Clinical Oncology, 2001.
- *85. Malhotra V, Dorr VJ, Lyss AP, Wooldridge JE, Anderson CM, Reynolds M, Perry, MC. Neoadjuvant and Adjuvant Chemotherapy (CT) with Doxorubicin and Docetaxel (DD) with Surgery and Radiation in Locally Advanced Breast Cancer. No. 1771 Proceedings of American Society of Clinical Oncology, 2001.

- *86. Anderson CM, Cunningham M, Peck R, Perry M, Evans W. Clinical Pathway for Hospitalized Terminally Ill. No. 3012 Proceedings of American Society of Clinical Oncology, 2001.
- *87. Perry MC, Ihde D, Herndon J II, Grossbard M, Grethein S, Atkins J, Vokes E, Green M. Paclitaxel/ifosfamide or vinorelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532, Lung Cancer 32(Suppl. 1)S-S74 pS67-S69. Abstracts of the 7th Central European Lung Cancer Conference, Prague, Czech Republic, 2001.
88. Malhotra V, Balaraman R, Johnson MI, Perry MC. Long term survival after heart transplantation (HTx) for anthracycline (A) induced cardiomyopathy in an adult with acute lymphoblastic leukemia (ALL). #4575, Blood, vol. 98, no. 11, p. 215b, November 16, 2001.
89. Schultheis CP, Perry MC, Wooldridge JE. Non-Hodgkin's lymphoma of the thyroid: the Ellis Fischel Cancer Center Experience. #4724, Blood, vol. 98, no. 11, p 248b, November 16, 2001.
- *90. Sikov WM, Akerley W, Kahanic S, Mangalik A, Arun B, Houston GA, Perry MC, Bertoli L, Kugler J. Multicenter, 3-arm randomized study of high-dose weekly paclitaxel (HDWP) versus standard-dose weekly paclitaxel (SDWP) for metastatic breast cancer (MBC). #134 Proceedings of American Society of Clinical Oncology, 2002.
- *91. Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic A, Komaki R, Brooks BJ, Perry MC, Marks RS, Livingston RB, Johnson DH. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer (NSCLC). #1202 Proceedings of American Society of Clinical Oncology, 2002.
- *93. Fleishman SB, Dresler C, Herndon JE, Kornblith AB, Kernstine K, Perry MC, Jablons D, Sugarbaker D, Haasler GT, Daniel TM. Quality of life (QOL) advantage of sclerosis for malignant pleural effusion (MPE) via talc thorascopy over chest tube infusion of talc slurry: a Cancer and Leukemia Group B study. #1418 Proceedings of American Society of Clinical Oncology, 2002.
- *94. Crawford J, Robert F, Perry M, Belani Cp, Sarokhan B. Epotetin alfa 40,000 u once weekly maintains hemoglobin in advanced non-small cell lung cancer patients receiving first-line chemotherapy. #2527 Proceedings of American Society of Clinical Oncology 2003.
- *95. Dragnev KH, Clamon G, Raez L, Jahanzeb M, O'Rourke M, Perry M, Carey M, Bendetto J, Wojtowwics-Praga S, Rigas JR. Docetaxel and cisplatin as induction therapy for stage IIIA (N2) non-small cell lung cancer (NSCLC). #2652 Proceedings of American Society of Clinical Oncology 2003.
- *96. Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIa non-small cell lung cancer (NSCLC) leads to higher than expected risk of death from intercurrent disease (DID). #2545 Proceedings of American Society of Clinical Oncology 2003.
- *97. Ramalingam S, Belani CP, Batrstis J, Perry MC, Larocca RV, Nattam SR, Rinaldi DA, Clark R, Mills G. Treatment of elderly non-small cell lung cancer (NSCLC) patients with three different schedules of weekly paclitaxel in combination with carboplatin:

sub-analysis of a randomized trial. #2693 Proceedings of American Society of Clinical Oncology 2003.

98. Johnson, CV, Shelton, T, Smith, CJ, Michaela, G, Perry, MC, Hoffman, TJ. Synergism of combined chemotherapy/radiotherapy in PC-3 prostate tumor xenografted mice. AACR, 2004. Submitted.

**APPEARS THIS WAY
ON ORIGINAL**